Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Eli Lilly director Kimberly H. Johnson acquired 15 shares of common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 15 shares of common stock on January 16, 2024.
• The shares were acquired at a price of $634.57 per share.
• These shares were acquired through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Johnson's separation from service.
• Following the transaction, Ms. Johnson directly owns 2,584 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of a director acquiring shares, which is generally a positive sign of confidence in the company. It is not a major event, but it is a positive indicator.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of a deferral plan aligns director compensation with long-term company performance.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

Director share acquisitions are a common practice in publicly traded companies, often used as part of compensation packages and to align director interests with shareholder value.

Comparison to Industry Standards

• Director share acquisitions are a standard practice across the pharmaceutical industry.
• Many companies use deferral plans to incentivize long-term performance and align director interests with shareholders.
• The specific details of deferral plans can vary, but the general concept is widely adopted.

Stakeholder Impact

• The share acquisition by a director can be viewed positively by shareholders, indicating confidence in the company's future.

Key Dates

Keywords

Eli Lilly, Director Share Acquisition, SEC Form 4, Kimberly H. Johnson, Director Deferral Plan, LLY, Stock Ownership